Business Daily Media

Men's Weekly

.

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics

  • Partnership expands spectrum of Secarna's capabilities for the development of targeted ASOs beyond antibodies and sugar molecules
  • New platform capabilities extend the reach of Secarna's antisense approaches, potentially offering new treatment options for a wider range of diseases
MARTINSRIED, GERMANY and OXFORD, UK - EQS Newswire - 28 May 2024 - Secarna Pharmaceuticals GmbH & Co.

KG (Secarna), a leading independent European antisense drug discovery and development company, and Orbit Discovery Ltd. (Orbit), a leader in the discovery of therapeutic peptide hits, today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.

The collaboration will leverage Orbit's expertise and bead-based peptide display engine for the identification, screening, and selection of cyclic peptides specific to a wide range of disease targets, to be paired with Secarna's ASO molecules. The addition of cyclic peptides to Secarna's proprietary ASO discovery and development platform will expand its therapeutic spectrum, positioning it to develop targeted antisense assets beyond modalities such as antibodies and sugar molecules, like GalNAc.

"We are very pleased to embark on this collaboration with Orbit Discovery, as the team's expertise in peptide discovery and development will further enhance our capabilities for the development of targeted antisense therapeutics", said Konstantin Petropoulos, CBO of Secarna Pharmaceuticals. "We look forward to working with Orbit to expand both the therapeutic potential and universe of targeted ASO therapeutics with highly specific, potent, safe and convenient therapeutic options available for patients who urgently need them."

Orbit's peptide discovery services enable the screening of large libraries of peptides through the combination of DNA-encoded libraries and bead-based presentation. The proprietary technology is uniquely equipped to address soluble targets and targets in situ, both on and in cells, allowing for faster discovery times of relevant peptide leads based on affinity screens and/or functional screens.

The collaboration not only strengthens Secarna's ability to create targeted antisense therapeutics, paired to cyclic peptides, but will also extend the reach of antisense approaches, potentially offering new treatment options for a wider range of diseases.

"Together with Secarna, we are excited to address the growing need for effective and highly specific targeted therapeutics, focused on enabling new options for the way innovative ASO therapies are delivered", said Dr. Neil Butt, Chief Executive Officer, Orbit Discovery. "This collaboration is further validation of our expertise in the discovery of targeting peptide conjugates, and adds to our growing portfolio of partners that share our goal of delivering a generation of therapeutics with lower toxicity and better tissue specificity that will ultimately be safer and more effective for patients globally."

Hashtag: #SecarnaPharmaceuticals

The issuer is solely responsible for the content of this announcement.

About Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals is the leading independent European next-generation antisense drug discovery and development company addressing high unmet medical needs in immuno-oncology and immunology, as well as viral, neurodegenerative and cardiometabolic diseases. Secarna's mission is to maximize the performance and output of its proprietary antisense oligonucleotide discovery and development platform to generate highly specific, safe, and efficacious best-in-class antisense therapies. With over 20 discovery and development programs, including both proprietary pipeline projects and partnered programs, Secarna focuses on targets in indications where antisense-based approaches have clear potential benefits over other therapeutic modalities.

About Orbit Discovery

Orbit Discovery Ltd is a peptide discovery company focused on the use of novel bead and microfluidic technology platforms to improve the throughput of functional screening. The Orbit technologies encompass target protein expression and purification, including multi-spanning membrane proteins; affinity screening to identify panels of target binding therapeutic candidates; and functional screening in cell-based assays. Orbit's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics for Partners and collaborators, these parties encompass large scale pharmaceutical and biotechnology companies. Orbit Discovery is based in the Oxford Science Park and benefits from the expertise and experience of its founders, Professor Graham Ogg (University of Oxford) and Professor Terry Rabbits (the Institute of Cancer Research). For more information, please visit:

News from Asia

Lee Kuan Yew School of Public Policy Releases Strategic Roadmap for ASEAN's 5G-AI Transformation

New Research Reveals US$130 Billion Economic Opportunity and Outlines Policy Framework to Accelerate Regional Digital Leadership by 2030SINGAPORE - Media OutReach Newswire - 22 July 2025 - The Le...

DFI Retail Group Holdings Limited Half-Year Results For The Six Months Ended 30 June 2025 And Announcement Of Special Dividend

Highlights 39% underlying earnings growth Increased contributions from associates, Health & Beauty and Food Health & Beauty delivered strong like-for-like (LFL...

HeyMax Acquires Hong Kong’s krip to Accelerate Regional Expansion into Loyalty and Rewards Market

HeyMax’s first acquisition fast-tracks its regional expansion, bringing over 6,000 credit card deals offered by over 3,000 merchants, and personalized loyalty experiences to consumers in Hong Kong ...

CUHK Faculty of Engineering: Advancing Innovation Through Research Excellence and Global Collaboration

HONG KONG SAR - Media OutReach Newswire - 23 July 2025 - The Faculty of Engineering at The Chinese University of Hong Kong (CUHK) continues to strengthen its position in global engineering educat...

Adecco Singapore Marks 40 Years of Enabling Talent and Business Growth

SINGAPORE - Media OutReach Newswire - 23 July 2025 - Adecco Singapore has officially commemorated its 40th anniversary with a stakeholder event held at the National Gallery Singapore. The occasion...

Samsung’s Solve for Tomorrow 2025 Youth Innovation Competition is Now On

SINGAPORE - Media OutReach Newswire - 23 July 2025 - Samsung Solve for Tomorrow 2025, the highly-anticipated youth innovation competition, is back for its ninth edition in Singapore! As the natio...

Jollibee Group Evolves its Corporate Brand to Help Power Global Growth

Brand update brings to life its global purpose and positioning as a unified group of brandsMANILA, PHILIPPINES - Media OutReach Newswire - 23 July 2025 - The Jollibee Group, one of the world's fas...

AECOM to enhance mobility across the Greater Bay Area by delivering the Hong Kong Section of Hong Kong–Shenzhen Western Rail Link (Hung Shui Kiu-Qianhai)

HONG KONG SAR - Media OutReach Newswire - 23 July 2025 - AECOM, the trusted global infrastructure leader, today announced that its joint venture with AtkinsRéalis has been awarded the consultancy ...

OCBC Hong Kong Unveils New Brand Campaign

Connected to “As One Group, OCBC Enables Aspiration All Across ASEAN and Greater China” Demonstrating the Unwavering Commitment in Realising Customer’s Aspirations HONG KONG SAR - Media...

X.me Foundation Empowers Global Expansion of the X.me Social Media Platform

SINGAPORE - Media OutReach Newswire - 23 July 2025 - X.me (https://x.me) is a social media platform where users can freely express themselves, share content, engage, and interact while earnin...

Baby boomers are driving development feasibility leading to larger apartments

As residential developers continue to grapple with feasibility issues on apartment projects, the sector is struggling to deliver volumes of new st...

Hays launches FY25/26 Salary Guide: ‘Salary Paradox’ deepens as pay rises fail Australians

Rising dissatisfaction with pay, progression and perks is fuelling a new wave of career change in FY25/26, as Australians demand more from employe...

Australian Businesses Still Stuck in the AI Hype Cycle

Data Governance Failures, ROI Gaps and Unclear Strategy Slowing Progress Despite artificial intelligence (AI) dominating headlines and boardroom ag...

How to ensure your manufacturing business survives international tariff turmoil

Optimising your operations in FY2026 will help you combat the challenges of a volatile trading environment. Up, down, in out…Since the commence...

Why Apptio is Enhancing Visibility into AI and Hybrid Cloud

AI investments have become a strategic priority for business with the mindset that if you're not using AI, you're falling behind. But according to...

Beyond borders: Building a scalable strategy for international hiring

For many Australian businesses, growth increasingly depends on thinking beyond local borders.  As wage pressures rise, and specialised talent pool...

Sell by LayBy